The FDA has accepted Teva and Medincell's New Drug Application for TEV-'749, a once-monthly subcutaneous olanzapine formulation for schizophrenia treatment that showed no need for post-injection monitoring in Phase 3 trials.
The FDA has approved pitolisant tablets for treating cataplexy in pediatric patients aged 6 and older with narcolepsy, making it the only non-scheduled therapy approved for both pediatric and adult narcolepsy patients with or without cataplexy.
Researchers identified shared white matter alterations in the corpus callosum as a common biomarker across schizophrenia and bipolar disorder, supporting the concept of a psychosis spectrum rather than distinct disorders.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06208176 |
HD-tDCS for Hallucinations |
NOT_YET_RECRUITING | NA |
| NCT05240339 |
Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD) |
COMPLETED | |
| NCT05210062 |
Impact of Closely Grouped, Iterative Exposures to Suxamethonium During ECT on the Sensitization to NMBA and the Development of Protective Antibodies |
UNKNOWN | |
| NCT04990414 |
Cognitive Behaviour Therapy for Voices and Dissociation |
COMPLETED | PHASE2 |
| NCT04399096 |
Sound and Vision: A Collaboration Between Service-users, Artists and the Public to Explore the Lived Experience of Hallucinations |
UNKNOWN | |
| NCT04352569 |
Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia |
RECRUITING | NA |
| NCT03807388 |
ReMindCare App for Patients From First Episode of Psychosis Unit. |
UNKNOWN | NA |
| NCT02974400 |
Evaluation of Internet-based Cognitive Behavioral Self-help Treatments for People With Psychosis |
COMPLETED | NA |
| NCT02460965 |
Understanding Hallucinations (Part II) |
UNKNOWN | |
| NCT01907568 |
Understanding Hallucinations (Part I) |
UNKNOWN |
